A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy

Mohammad A.I. Al-Hatamleh; Suhana Ahmad; Jennifer C. Boer; Jitkang Lim; Xin Chen; Magdalena Plebanski; Rohimah Mohamud

doi:10.1155/2019/6313242

A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy

Mohammad A.I. Al-Hatamleh, Suhana Ahmad, Jennifer C. Boer, Jitkang Lim, Xin Chen, Magdalena Plebanski, Rohimah Mohamud

Immunology Alfred Hospital

Research output: Contribution to journal › Review Article › Research › peer-review

24 Citations (Scopus)

Abstract

In the past decade, nanomedicine research has provided us with highly useful agents (nanoparticles) delivering therapeutic drugs to target cancer cells. The present review highlights nanomedicine applications for breast cancer immunotherapy. Recent studies have suggested that tumour necrosis factor (TNF) and its receptor 2 (TNFR2) expressed on breast cancer cells have important functional consequences. This cytokine/receptor interaction is also critical for promoting highly immune-suppressive phenotypes by regulatory T cells (Tregs). This review generally provides a background for nanoparticles as potential drug delivery agents for immunomodulators and further discusses in depth the potential of TNF antagonists delivery to modulate TNF-TNFR2 interactions and inhibit breast cancer progression.

Original language	English
Article number	6313242
Number of pages	14
Journal	Journal of Oncology
Volume	2019
DOIs	https://doi.org/10.1155/2019/6313242
Publication status	Published - 1 Jan 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1155/2019/6313242

283364283-oaFinal published version, 2.72 MB

Cite this

@article{a3467e2c46c44a25a992347165e81a2f,

title = "A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy",

abstract = "In the past decade, nanomedicine research has provided us with highly useful agents (nanoparticles) delivering therapeutic drugs to target cancer cells. The present review highlights nanomedicine applications for breast cancer immunotherapy. Recent studies have suggested that tumour necrosis factor (TNF) and its receptor 2 (TNFR2) expressed on breast cancer cells have important functional consequences. This cytokine/receptor interaction is also critical for promoting highly immune-suppressive phenotypes by regulatory T cells (Tregs). This review generally provides a background for nanoparticles as potential drug delivery agents for immunomodulators and further discusses in depth the potential of TNF antagonists delivery to modulate TNF-TNFR2 interactions and inhibit breast cancer progression.",

author = "Al-Hatamleh, {Mohammad A.I.} and Suhana Ahmad and Boer, {Jennifer C.} and Jitkang Lim and Xin Chen and Magdalena Plebanski and Rohimah Mohamud",

year = "2019",

month = jan,

day = "1",

doi = "10.1155/2019/6313242",

language = "English",

volume = "2019",

journal = "Journal of Oncology",

issn = "1687-8450",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy

AU - Al-Hatamleh, Mohammad A.I.

AU - Ahmad, Suhana

AU - Boer, Jennifer C.

AU - Lim, Jitkang

AU - Chen, Xin

AU - Plebanski, Magdalena

AU - Mohamud, Rohimah

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In the past decade, nanomedicine research has provided us with highly useful agents (nanoparticles) delivering therapeutic drugs to target cancer cells. The present review highlights nanomedicine applications for breast cancer immunotherapy. Recent studies have suggested that tumour necrosis factor (TNF) and its receptor 2 (TNFR2) expressed on breast cancer cells have important functional consequences. This cytokine/receptor interaction is also critical for promoting highly immune-suppressive phenotypes by regulatory T cells (Tregs). This review generally provides a background for nanoparticles as potential drug delivery agents for immunomodulators and further discusses in depth the potential of TNF antagonists delivery to modulate TNF-TNFR2 interactions and inhibit breast cancer progression.

AB - In the past decade, nanomedicine research has provided us with highly useful agents (nanoparticles) delivering therapeutic drugs to target cancer cells. The present review highlights nanomedicine applications for breast cancer immunotherapy. Recent studies have suggested that tumour necrosis factor (TNF) and its receptor 2 (TNFR2) expressed on breast cancer cells have important functional consequences. This cytokine/receptor interaction is also critical for promoting highly immune-suppressive phenotypes by regulatory T cells (Tregs). This review generally provides a background for nanoparticles as potential drug delivery agents for immunomodulators and further discusses in depth the potential of TNF antagonists delivery to modulate TNF-TNFR2 interactions and inhibit breast cancer progression.

UR - http://www.scopus.com/inward/record.url?scp=85066978186&partnerID=8YFLogxK

U2 - 10.1155/2019/6313242

DO - 10.1155/2019/6313242

M3 - Review Article

AN - SCOPUS:85066978186

VL - 2019

JO - Journal of Oncology

JF - Journal of Oncology

SN - 1687-8450

M1 - 6313242

ER -

A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy

Abstract

UN SDGs

Access to Document

Other files and links

Cite this